Keyword Analysis & Research: cc90011
Keyword Research: People who searched cc90011 also searched
Search Results related to cc90011 on Search Engine
-
Discovery of CC-90011: A Potent and Selective …
https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00978
WEBOct 9, 2020 · CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor … Author: Toufike Kanouni, Christophe Severin, Robert W. Cho, Natalie Y.-Y. Yuen, Jiangchun Xu, Lihong Shi, Ch... Publish Year: 2020
Author: Toufike Kanouni, Christophe Severin, Robert W. Cho, Natalie Y.-Y. Yuen, Jiangchun Xu, Lihong Shi, Ch...
Publish Year: 2020
DA: 52 PA: 23 MOZ Rank: 39
-
Discovery of CC-90011: A Potent and Selective …
https://pubmed.ncbi.nlm.nih.gov/33034194/
WEBDec 10, 2020 · CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and … Author: Toufike Kanouni, Christophe Severin, Robert W. Cho, Natalie Y.-Y. Yuen, Jiangchun Xu, Lihong Shi, Ch... Publish Year: 2020
Author: Toufike Kanouni, Christophe Severin, Robert W. Cho, Natalie Y.-Y. Yuen, Jiangchun Xu, Lihong Shi, Ch...
Publish Year: 2020
DA: 85 PA: 95 MOZ Rank: 73
-
Clinical activity of CC-90011, an oral, potent, and …
https://pubmed.ncbi.nlm.nih.gov/35737639/
WEBPMCID: PMC9540525. DOI: 10.1002/cncr.34366. Abstract. Background: CC-90011 is an oral, potent, selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1) that …
DA: 78 PA: 76 MOZ Rank: 1
-
Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and
https://ashpublications.org/blood/article/138/Supplement%201/4430/482277/Phase-1-2-Study-Investigating-CC-90011-a-Potent
WEBNov 5, 2021 · CC-90011 is a potent, selective, and reversible oral inhibitor of LSD1 that has shown antitumor effects in solid-tumor and AML cell-line models. CC-90011 …
DA: 52 PA: 16 MOZ Rank: 82
-
MA18.10 Phase 2 Multicohort Study of CC-90011, a …
https://www.jto.org/article/S1556-0864(23)01053-5/fulltext
WEBCC-90011 is a potent, selective, and reversible oral inhibitor of lysine-specific histone demethylase 1A (LSD1). It is well tolerated and clinically active in some patients with …
DA: 93 PA: 91 MOZ Rank: 77
-
Clinical activity of CC‐90011, an oral, potent, and …
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34366
WEBJun 23, 2022 · CC-90011 is a potent, selective, and reversible oral LSD1 inhibitor 20 that has been shown to increase expression of tumor-suppressing genes and decrease expression of tumor-promoting genes, …
DA: 63 PA: 3 MOZ Rank: 100
-
Phase I study of CC-90011 in patients with ... - Annals of Oncology
https://www.annalsofoncology.org/article/S0923-7534(19)30018-3/fulltext
WEBBackground: CC-90011 is a potent, selective, reversible oral inhibitor of the epigenetic target, lysine-specific demethylase 1A (LSD1) that has demonstrated anti-proliferative …
DA: 45 PA: 11 MOZ Rank: 48
-
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, …
https://pubmed.ncbi.nlm.nih.gov/33046517/
WEBJan 15, 2021 · CC-90011 is a potent, selective, and reversible oral LSD1 inhibitor. We examined CC-90011 in advanced solid tumors and relapsed/refractory (R/R) non …
DA: 18 PA: 51 MOZ Rank: 81
-
7O Updated results from phase I study of CC-90011 in …
https://www.annalsofoncology.org/article/S0923-7534(21)00029-6/fulltext
WEBCC-90011, an oral, potent, selective, and reversible inhibitor of lysine-specific demethylase 1A, was well tolerated and showed antitumor activity in the first-in-human CC-90011-ST …
DA: 80 PA: 28 MOZ Rank: 75
